NicOx Research Institute

Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. The company's primary expertise lies in its proprietary nitric oxide (NO)-donating platform, which it applies to existing compounds to enhance their efficacy and safety profiles. Its lead commercial product, Vyzulta, is a first-in-class nitric oxide-donating prostaglandin analog for glaucoma, licensed globally to Bausch + Lomb. Nicox is currently advancing a pipeline of late-stage candidates, most notably NCX 470 for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also markets Zerviate for allergic conjunctivitis through various regional partners. Headquartered in France, Nicox maintains a specialized R&D center, the Nicox Research Institute, in Italy to drive its drug discovery efforts.